Your browser is no longer supported. Please, upgrade your browser.
Settings
ATOS [NASD]
Atossa Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.16 Insider Own0.04% Shs Outstand120.82M Perf Week-6.29%
Market Cap396.30M Forward P/E- EPS next Y-0.18 Insider Trans-68.45% Shs Float- Perf Month2.50%
Income-26.10M PEG- EPS next Q-0.04 Inst Own31.60% Short Float- Perf Quarter-44.31%
Sales- P/S- EPS this Y2.70% Inst Trans198.91% Short Ratio1.55 Perf Half Y31.20%
Book/sh1.18 P/B2.78 EPS next Y-5.90% ROA-30.50% Target Price- Perf Year34.43%
Cash/sh1.18 P/C2.78 EPS next 5Y- ROE-32.70% 52W Range0.81 - 9.80 Perf YTD245.26%
Dividend- P/FCF- EPS past 5Y52.40% ROI- 52W High-66.07% Beta2.24
Dividend %- Quick Ratio81.20 Sales past 5Y- Gross Margin- 52W Low310.49% ATR0.29
Employees4 Current Ratio81.20 Sales Q/Q- Oper. Margin- RSI (14)44.03 Volatility8.06% 8.40%
OptionableYes Debt/Eq0.00 EPS Q/Q86.40% Profit Margin- Rel Volume0.15 Prev Close3.28
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume15.83M Price3.33
Recom2.00 SMA20-7.73% SMA50-11.39% SMA2008.55% Volume1,121,032 Change1.37%
Jan-26-18Initiated Maxim Group Buy $2
Sep-13-21 05:47PM  
Sep-10-21 01:48PM  
Sep-07-21 05:20PM  
Sep-02-21 09:30AM  
Aug-25-21 04:11PM  
Aug-13-21 09:30AM  
Aug-05-21 09:30AM  
Jul-15-21 09:00AM  
Jul-09-21 10:54AM  
Jul-07-21 09:30AM  
Jun-16-21 09:00AM  
Jun-14-21 06:13PM  
Jun-11-21 09:00AM  
Jun-09-21 09:00AM  
Jun-08-21 01:33AM  
Jun-07-21 09:00AM  
Jun-01-21 04:39PM  
May-27-21 01:30PM  
May-21-21 09:00AM  
May-14-21 09:15AM  
09:00AM  
May-11-21 09:30AM  
Apr-30-21 09:30AM  
Apr-08-21 09:30AM  
Mar-31-21 09:30AM  
Mar-30-21 09:40AM  
Mar-22-21 08:30AM  
Mar-11-21 09:30AM  
Mar-01-21 09:55AM  
Feb-25-21 09:00AM  
Feb-10-21 09:30AM  
Feb-03-21 09:30AM  
Feb-02-21 09:30AM  
Jan-29-21 09:30AM  
08:00AM  
Jan-27-21 09:00AM  
Jan-25-21 09:30AM  
Jan-08-21 06:02AM  
Jan-06-21 09:15AM  
Dec-17-20 09:15AM  
Dec-09-20 11:28PM  
Dec-08-20 09:45PM  
Nov-17-20 08:00AM  
Nov-13-20 09:30AM  
Nov-10-20 09:30AM  
Oct-28-20 07:03AM  
Oct-19-20 09:30AM  
Oct-07-20 09:30AM  
Oct-02-20 09:20AM  
Sep-21-20 06:09PM  
Sep-17-20 09:30AM  
Sep-14-20 08:00AM  
Sep-08-20 08:00AM  
Sep-01-20 09:30AM  
Aug-31-20 06:12PM  
Aug-26-20 09:30AM  
Aug-17-20 09:30AM  
Aug-13-20 09:30AM  
Aug-05-20 11:04AM  
Aug-03-20 09:30AM  
Jul-30-20 09:30AM  
Jul-27-20 09:30AM  
Jul-21-20 10:12PM  
Jul-16-20 09:15AM  
Jul-15-20 09:30AM  
Jul-08-20 09:30AM  
Jun-13-20 08:05AM  
Jun-11-20 09:30AM  
Jun-05-20 03:49PM  
May-29-20 08:00AM  
May-28-20 09:30AM  
May-20-20 09:30AM  
May-13-20 09:30AM  
May-07-20 09:30AM  
08:00AM  
Apr-27-20 08:00AM  
Apr-22-20 03:40PM  
Apr-20-20 08:00AM  
Apr-17-20 10:51AM  
Apr-16-20 08:00AM  
Apr-02-20 08:00AM  
Mar-30-20 08:00AM  
Mar-26-20 08:00AM  
Mar-13-20 08:30AM  
Mar-02-20 08:30AM  
Feb-05-20 08:00AM  
Feb-04-20 05:10PM  
Jan-22-20 08:30AM  
Jan-06-20 08:00AM  
Dec-19-19 08:30AM  
Dec-16-19 11:09AM  
Dec-05-19 08:30AM  
Nov-13-19 08:00AM  
Oct-23-19 08:30AM  
Oct-16-19 08:30AM  
Oct-15-19 08:30AM  
Sep-30-19 08:30AM  
Sep-06-19 08:30AM  
Sep-03-19 08:00AM  
Aug-13-19 01:26PM  
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WEAVER GREGORY LDirectorJul 02Option Exercise2.22164,581365,337164,581Jul 07 04:29 PM
WEAVER GREGORY LDirectorJul 02Sale5.58107,497599,8330Jul 07 04:29 PM